Our Team
Management

Ehud Marom
Chairman & CEO

Uri Danon
Executive VP

Nir Bernstein
VP Finance

Shai Rubnov, Ph.D.
VP R&D

Alex Mogle
VP Corporate Development

Laura Popper, M.D.
VP Clinical Development

Nadav Bleich Kimelman, DMD, Ph.D.
VP Pharmaceutical Development

Rut Hayden Ideses, Ph.D.
Quality Assurance Manager
Directors
Ehud Marom
Uri Yaron, Ph.D.
Alex Mogle
Itamar Borowitz, Ph.D.
Dov Pekelman, Ph.D.
Itay Attar, CPA
Scientific Advisory Board
Professor Jerry S. Wolinksy,
M.D., Ph.D.
Professor Tamir Ben-Hur,
M.D., Ph.D.

Ehud Marom
Chairman & CEO
Ehud Marom is one of our founders and has served as our chief executive officer and as chairman of our board of directors since our inception in January 2008. Mr. Marom has over 40 years of management and operational experience in the life sciences industry. Prior to our founding, Mr. Marom served in various senior positions at multinational pharmaceutical companies, including as vice president of two divisions at Teva Pharmaceutical Industries Ltd. from 1992 to 1995, where he launched Copaxone (with current sales of $4 billion per year) and was the head of the Copaxone global operation team and headed the global operations of Teva Pharmaceutical Industries Ltd.’s chemical division. From 2000 to 2002, Mr. Marom served as president of Peptor Ltd., where he led the pharmaceutical development of the innovative diabetes product, DiaPep. From 2002 to 2004, Mr. Marom served as chief executive officer of Gamida-Cell Ltd., a stem cell development company. From 2005 to 2007, Mr. Marom served as chief executive officer of Makhteshim, a company with annual sales of $1 billion and the world’s leader in branded off-patent crop protection solutions (which later became Makhteshim-Agan Industries Ltd. and has since been acquired by China National Agrochemical Corporation, a subsidiary of China National Chemical Corporation). Mr. Marom served as vice president of supply of Makhteshim-Agan Industries Ltd. from 2005 to 2009. He helped guide the product of Pharma Two B, P2B001, for the treatment of early diagnosed Parkinson disease, through a successful phase IIb pivotal trial expected to be registered via the 505(b)(2) regulatory pathway. Mr. Maron serves as well as chief executive officer and chairman of Stem Cell Medicine Ltd. Ehud has a B.Sc. in chemical engineering with honors, from the Technion, Israel.

Uri Danon
Executive VP

Nir Bernstein
VP Finance

Shai Rubnov
PhD, VP R&D

Alex Mogle
VP Corporate Development

Laura Popper, M.D.
Medical Director

Nadav Bleich Kimelman, DMD, Ph.D.
VP Pharmaceutical Development
Nadav Bleich Kimelman has served as VP Pharmaceutical Development since 2021. Dr. Bleich Kimelman joined Mapi Pharma in 2012 and served in various positions from Depot Formulations Team Leader to Associate VP. In those capacities, Dr. Bleich Kimelman was responsible for the Company’s Depot Formulations line production development and scale-up, as well as for the company’s supply chain and production planning. Additionally, Dr. Bleich Kimelman managed the pre-clinical as well as the clinical studies for this product line. Dr. Bleich Kimelman graduated from the DMD-PhD program at the Hebrew University of Jerusalem, Israel. He is a certified Doctor of Dental Medicine and was awarded for Excellent PhD thesis.

Rut Hayden Ideses, Ph.D.
Quality Assurance Manager
Rut Hayden Ideses serves as our Quality Assurance Manager since 2016. Dr. Hayden Ideses served in various QA positions in leading Israeli pharmaceutical manufacturers. From 2002 to 2016 she served as Quality Assurance Manager at Trima Ltd. From 1995 to 2002 served as R&D Quality Assurance Manager at Dexcel Pharma Ltd and from 1991 to 1995 she served as Quality Control Manager at Teva’s API Division. Past experience includes Team Leader at Makhteshim Chemical Works R&D Department. Dr. Hayden Ideses holds a PhD in Organic Chemistry from the Ben Gurion University in Beer Sheva with post-doctoral training from the Marine Biology Institute in Eilat, Israel.
Ehud Marom
Itamar Borowitz, Ph.D.
Uri Yaron, Ph.D.
Uri is a HealthTech and Life Sciences investment Executive who serves on multiple Boards. In his previous role he served as the WW President of Biosense Webster (BWI), a member of the Johnson & Johnson Family of Companies. Uri joined BWI in 1996, a year prior to its acquisition by J&J. Prior to his WW President role, Uri has held several positions of increasing responsibilities in R&D, Business Development and General Management at Biosense Webster, Cordis, Cerenovus, Mentor, Acclarent, ASP & Sterilmed. Uri is known as a strategic leader who established outstanding relationships with both customers and external partners, creating significant value for J&J in the cardiovascular space. He has a proven track record of driving innovation and growth and adapting the company’s business model to a rapidly changing and increasingly challenging external environment. Under Uri’s Leadership, BWI teams have won five Johnson Medals, the most prestigious award given for research & development excellence within J&J.
Uri holds a PhD in Physics from the Hebrew University of Jerusalem, summa cum laude. Prior to joining BWI, Uri was a Member of the Technical Staff at the Micro-Physics Research Lab of AT&T Bell Laboratories. He is a co-author of over 40 peer-reviewed papers, including papers in Nature and Physical Review Letters, and a co-inventor of over 10 US patents. Uri serves on the Board of Directors of the Western States of the American Heart Association. He was the Chairperson of the 2020 LA Heart & Stroke Walk. In addition, Uri teaches an MBA course at the BioMed MBA Program of the Hebrew University, and coaches senior combat officers of the Israeli Defense Forces.
Dov Pekelman
Alex Mogle
Itay Attar, CPA
Prof. Jerry S. Wolinsky, MD, PhD
Prof. Tamir Ben-Hur, MD, PhD